MedWatch

New FDA requirements could provide opportunities for Genmab, CEO says

Genmab CEO Jan van de Winkel thinks the FDA’s new project, Optimus, could be good for the firm, as it will require more work do be done to find the optimal dosage of cancer treatments.

Photo: PR / Genmab

New guidelines from the US Food and Drug Administration (FDA) concerning the development of cancer treatments could have a big impact on the sector, says Genmab’s CEO Jan van de Winkel.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs